Roche Holding (ROP) Stock Overview

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. More details

ROP fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	4/6
Financial Health	4/6
Dividends	5/6

Rewards

Trading at 61.4% below our estimate of its fair value

Earnings are forecast to grow 10.3% per year

Pays a reliable dividend of 2.85%

Risk Analysis

Has a high level of debt

ROP Community Fair Values

Create Narrative

See what 36 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

7.0% undervalued

AnalystConsensusTarget

1mo ago

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

19.6% undervalued

AnalystHighTarget

4mo ago

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Top Community Narratives

Roche Holding

2.6% undervalued

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

kapirey

Published 12 May

Read Narrative

Top Community Narratives

Roche Holding

2.6% undervalued

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

kapirey

Published 12 May

Read Narrative

Top Analyst Narratives

7.0% undervalued

AnalystConsensusTarget

1mo ago

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

19.6% undervalued

AnalystHighTarget

4mo ago

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

View all narratives

Roche Holding AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Roche Holding
Historical stock prices
Current Share Price	CHF 344.20
52 Week High	CHF 375.80
52 Week Low	CHF 252.20
Beta	0.35
1 Month Change	-3.07%
3 Month Change	5.55%
1 Year Change	30.13%
3 Year Change	31.70%
5 Year Change	0.38%
Change since IPO	1,218.77%

Recent updates

Narrative Update • Aug 24

ROP: Partnership And Pipeline Execution Risk Will Likely Cap Future Upside

Analysts have nudged their fair value estimate for Roche Holding to CHF 267.89 from CHF 260.11, citing a mix of higher assumed revenue growth, a slightly adjusted discount rate, modestly lower profit margin expectations, and a marginally higher future P/E. Analyst Commentary Recent Street research around Roche Holding offers a mixed picture for investors, with some firms highlighting potential growth drivers while others flag valuation and execution risks.

Narrative Update • Aug 10

ROP: Pipeline Partnerships And Oncology Catalysts Will Shape Measured 2027 Outlook

Analysts have lifted their fair value estimate for Roche Holding to CHF 370.31 from CHF 359.22, citing a combination of visible growth, incremental pipeline contributions including giredestrant, and recent partnership activity. They view these factors as supporting revenue growth assumptions and profit margin resilience, despite a slightly higher discount rate and a modestly lower future P/E multiple.

Analysis Article • Jul 31

Roche Holding (VTX:ROP) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Investors signalled that they were pleased with Roche Holding AG's ( VTX:ROP ) most recent earnings report. According...

Narrative Update • Jul 27

ROP: Partnership Reliance And Pipeline Skepticism Will Likely Restrain Future Upside

Analysts lifted their fair value estimate for Roche Holding, implying a new price target of about CHF 260. They incorporated updated assumptions on revenue growth, margins and P/E following a series of partnership-focused research notes around the company's Nurix collaboration and a recent HSBC rating change.

Analysis Article • Jul 27

Analyst Estimates: Here's What Brokers Think Of Roche Holding AG (VTX:ROP) After Its Half-Yearly Report

Investors in Roche Holding AG ( VTX:ROP ) had a good week, as its shares rose 7.1% to close at CHF355 following the...

Narrative Update • Jul 10

ROP: Pipeline Partnerships And Oncology Data Will Shape Balanced Outlook

Analysts have modestly lifted their fair value estimate for Roche Holding to CHF 359.22 from CHF 352.00, citing updated assumptions around revenue growth, profit margins and future P/E, along with mixed but generally constructive readthroughs from recent pipeline and partnership research. Analyst Commentary Recent Street research around Roche Holding points to a mixed but constructive setup, with optimism around specific products and partnerships balanced by more cautious views on the risk and timing of future growth and execution.

Narrative Update • Jun 26

ROP: External Oncology Collaborations Will Likely Cap Near Term Upside

Analysts have updated their fair value estimate for Roche Holding to CHF 253.81 from CHF 295.00, reflecting refreshed assumptions on revenue growth, margins, and future P/E multiples in light of recent co-development agreements with partners such as Nurix Therapeutics. Analyst Commentary Recent Street research around Roche Holding and its partners gives you a mixed picture, with enthusiasm for the co-development agreements alongside more cautious voices highlighting execution and valuation risks.

New Narrative • May 12

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Investment Memo – Roche Holding AG (Pharmaceutical Division / “Roche Pharma”) 1. Executive Summary Roche is a leading global pharmaceutical and diagnostics company with a strong focus on oncology, immunology, neuroscience, and rare diseases.

New Narrative • Apr 19

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Catalysts About Roche Holding Roche is a global healthcare company focused on pharmaceuticals and diagnostics across oncology, neurology, immunology, ophthalmology and cardiometabolic diseases. What are the underlying business or industry changes driving this perspective?

New Narrative • Apr 04

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Catalysts About Roche Holding Roche Holding is a global healthcare company with large pharmaceutical and diagnostics businesses focused on prescription medicines, biologics and lab testing solutions. What are the underlying business or industry changes driving this perspective?

New Narrative • Mar 21

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Catalysts About Roche Holding Roche Holding is a global healthcare group focused on pharmaceuticals and diagnostics, with a large late stage pipeline and extensive manufacturing and R&D infrastructure. What are the underlying business or industry changes driving this perspective?

Shareholder Returns

	ROP	CH Pharmaceuticals	CH Market
7D	-3.6%	-7.5%	-3.5%
1Y	30.1%	21.4%	11.0%

Return vs Industry: ROP exceeded the Swiss Pharmaceuticals industry which returned 21.4% over the past year.

Return vs Market: ROP exceeded the Swiss Market which returned 11% over the past year.

Price Volatility

Is ROP's price volatile compared to industry and market?
ROP volatility
ROP Average Weekly Movement	3.4%
Pharmaceuticals Industry Average Movement	4.5%
Market Average Movement	3.9%
10% most volatile stocks in CH Market	7.5%
10% least volatile stocks in CH Market	2.0%

Stable Share Price: ROP has not had significant price volatility in the past 3 months compared to the Swiss market.

Volatility Over Time: ROP's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1896	103,249	Thomas Schinecker	www.roche.com

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions.

Roche Holding AG Fundamentals Summary

How do Roche Holding's earnings and revenue compare to its market cap?
ROP fundamental statistics
Market cap	CHF 275.14b
Earnings (TTM)	CHF 12.34b
Revenue (TTM)	CHF 62.96b

22.2x

P/E Ratio

4.4x

P/S Ratio

Is ROP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ROP income statement (TTM)
Revenue	CHF 62.96b
Cost of Revenue	CHF 16.26b
Gross Profit	CHF 46.70b
Other Expenses	CHF 34.35b
Earnings	CHF 12.34b

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

Oct 22, 2026

Earnings per share (EPS)	15.49
Gross Margin	74.17%
Net Profit Margin	19.60%
Debt/Equity Ratio	86.6%

How did ROP perform over the long term?

See historical performance and comparison

Dividends

2.8%

Current Dividend Yield

63%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/13 02:04
End of Day Share Price	2026/09/11 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Roche Holding AG is covered by 45 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
John Staszak	Argus Research Company
Gerhard Schwarz	Baader Helvea Equity Research
Mark Purcell	Barclays

Roche Holding (ROP) Stock Overview

Rewards

Risk Analysis

Analyst Price Targets

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Top Community Narratives

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Top Community Narratives

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Top Analyst Narratives

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Roche Holding AG Competitors

Novartis

Galderma Group

Sandoz Group

Dottikon ES Holding

Price History & Performance

Recent News & Updates

FDA Priority Review Advances Roche Enspryng Bid for First MOGAD Therapy Approval

Roche Receives U.S. FDA Priority Review for Enspryng for MOGAD

Roche to Launch Phase 1 Combination Trial With Treeline in B-Cell Lymphomas

New minor risk - Dividend sustainability

Roche Presents Two-Year Results From The SALWEEN Study Of Vabysmo In Polypoidal Choroidal Vasculopathy

Roche Receives FDA Approval For Companion Diagnostic Tests to Identify Patients With HER2-Positive Metastatic Gastroesophageal Adenocarcinoma Eligible For ZIIHERA

Recent updates

FDA Priority Review Advances Roche Enspryng Bid for First MOGAD Therapy Approval

Roche Receives U.S. FDA Priority Review for Enspryng for MOGAD

Roche to Launch Phase 1 Combination Trial With Treeline in B-Cell Lymphomas

New minor risk - Dividend sustainability

Roche Presents Two-Year Results From The SALWEEN Study Of Vabysmo In Polypoidal Choroidal Vasculopathy

Roche Receives FDA Approval For Companion Diagnostic Tests to Identify Patients With HER2-Positive Metastatic Gastroesophageal Adenocarcinoma Eligible For ZIIHERA

Roche Licenses Hanmi Obesity Drug Candidate in $2.3 Billion Deal With Genentech

Roche Receives FDA Clearance For Elecsys Ptau217 Blood Test For Alzheimer’s Disease Assessment

ROP: Partnership And Pipeline Execution Risk Will Likely Cap Future Upside

Genentech to Expand Hillsboro Facility With $750 Million Investment for Advanced Injectables

Genentech Reaches Construction Milestone for $2 Billion North Carolina Biomanufacturing Facility

ChemoMetec and Roche Team Up on Cedex Bio Analyzer Integration Collaboration

ROP: Pipeline Partnerships And Oncology Catalysts Will Shape Measured 2027 Outlook

Roche Holding Teams With Evexta Bio for Phase 1b Breast Cancer Drug Trial

Roche Holding (VTX:ROP) Is Posting Promising Earnings But The Good News Doesn’t Stop There

ROP: Partnership Reliance And Pipeline Skepticism Will Likely Restrain Future Upside

Analyst Estimates: Here's What Brokers Think Of Roche Holding AG (VTX:ROP) After Its Half-Yearly Report

Roche Gains FDA Clearance for cobas BV/CV Molecular Vaginitis Diagnostic

First half 2026 earnings released

CHMP Backs EU Approval for Susvimo Continuous Eye Treatment in Roche Milestone

Roche Receives Positive CHMP Recommendation For Susvimo For Neovascular Age-Related Macular Degeneration

Roche Receives FDA Clearance For The Cobas BV/CV Assay Enabling Fast And Highly Accurate Vaginitis Diagnosis

Roche Names Dan Malarek CEO of Diagnostics North America as Leadership Team Shifts

FDA Sets Priority Review for Roche’s Gazyva in Rare Kidney Disease Therapy Decision

Roche Announces FDA Grants Priority Review to Roche’s Gazyva/Gazyvaro for Adults with Primary Membranous Nephropathy

Roche Unveils First Fully Automated HDV Test for Severe Hepatitis Detection and Monitoring

Roche Introduces Cobas Hepatitis D Virus Test for Use on Cobas 5800/6800/8800 Systems

ROP: Pipeline Partnerships And Oncology Data Will Shape Balanced Outlook

Roche Receives CE Mark for Automated Tuberculosis Blood Test Across Europe

Roche Presents New Data in Alzheimer’S Disease Portfolio At Aaic 2026

Roche Reports Positive Results from Phase Iii Krascendo 1 Study Evaluating Divarasib Against Approved Kras G12c Inhibitors in Previously Treated Kras G12c Non-Small Cell Lung Cancer

FDA Accepts Priority Review for Roche Enspryng in Thyroid Eye Disease Expansion

Roche Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Enspryng for Thyroid Eye Disease

Roche Announces Launch Of AXELIOS 1 Sequencing Platform

ROP: External Oncology Collaborations Will Likely Cap Near Term Upside

Roche Backs Orano Med to Advance Lead-212 Radiopharma Cancer Therapies

Roche Receives FDA Acceptance for Supplemental Biologics License Application For Lunsumio And Polivy Combination For Relapsed Or Refractory Large B-Cell Lymphoma

Roche Receives FDA Approval for the First Companion Diagnostic to Assess PTEN Protein in People Living with Prostate Cancer

Roche Expands Cancer Diagnostics and Awaits FDA Decision on Tecentriq for Colon Cancer

Roche Announces FDA Grants Priority Review For Roche's Tecentriq For A Certain Type Of Stage III Colon Cancer

Roche Advances Breast Cancer Pipeline With FDA Review for Giredestrant and Companion Diagnostic Approval

Roche Receives FDA Acceptance For New Drug Application For Giredestrant In ER-Positive Early-Stage Breast Cancer

Foundation Medicine Receives Fda Approval for Foundationone Cdx as Companion Diagnostic for Itovebi (Inavolisib) in Combination with Palbociclib and Fulvestrant

Roche Launches the Liver Disease Panel Suite of Certified Algorithms to Support Chronic Liver Disease Management

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Roche Receives CE Mark For Elecsys Ptau217 Blood Test For Alzheimer’S Disease Pathology

Roche Holding AG (SWX:ROP) entered into a definitive merger agreement to acquire PathAI, Inc. for $1.1 billion.

Roche Showcases Ophthalmology Portfolio At Arvo 2026

Roche Announces FDA Acceptance of Application for Gazyva Gazyvaro for Treatment of Systemic Lupus Erythematosus

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Roche Receives CE Mark for New Elecsys NfL Blood Test to Detect Neuroinflammation in Multiple Sclerosis